Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for progression-free survival and overall survival. Several techniques are available for the detection of MRD inside (next-generation sequencing, flow cytometry) and outside (PET/CT, magnetic resonance) the bone marrow, and their complementary use allows a precise definition of the efficacy of anti-myeloma treatments. This review summarizes MRD data and results from previous clinical trials, highlights open issues related to the role of MRD in MM and discusses how MRD could be implemented in clinical practice to inform on patient prognosis and drive therapeutic decisions.
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
Mina, Roberto
Co-first
;Oliva, StefaniaCo-first
;Boccadoro, MarioLast
2020-01-01
Abstract
Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for progression-free survival and overall survival. Several techniques are available for the detection of MRD inside (next-generation sequencing, flow cytometry) and outside (PET/CT, magnetic resonance) the bone marrow, and their complementary use allows a precise definition of the efficacy of anti-myeloma treatments. This review summarizes MRD data and results from previous clinical trials, highlights open issues related to the role of MRD in MM and discusses how MRD could be implemented in clinical practice to inform on patient prognosis and drive therapeutic decisions.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mina et al 2020 - MRD - OA - jcm-09-02142-v2.pdf
Accesso aperto
Descrizione: [Published Vsn.] Mina R et al. J Clin Med . 2020 Aug 13;9(8):2630. doi: 10.3390/jcm9072142. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Open access article, Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Available at: https://www.mdpi.com/2077-0383/9/7/2142 | https://doi.org/10.3390/jcm9072142 . See also erratum: J Clin Med . 2020 Aug 13;9(8):2630. doi: 10.3390/jcm9082630.
Tipo di file:
PDF EDITORIALE
Dimensione
256.34 kB
Formato
Adobe PDF
|
256.34 kB | Adobe PDF | Visualizza/Apri |
|
ERRATUM of Mina et al 2020 - MRD - OA - jcm-09-02630.pdf
Accesso aperto
Descrizione: [Published Vsn.] Erratum. Mina R et al. J Clin Med . 2020 Aug 13;9(8):2630. doi: 10.3390/jcm9082630. ERRATUM of: Mina R et al. J Clin Med . 2020 Aug 13;9(8):2630. doi: 10.3390/jcm9072142. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Open access article, Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Available at: https://www.mdpi.com/2077-0383/9/7/2142 | https://doi.org/10.3390/jcm9072142 .
Tipo di file:
PDF EDITORIALE
Dimensione
175.61 kB
Formato
Adobe PDF
|
175.61 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
